Centrexion Therapeutics Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid, non-addictive therapies in active development. Centrexion Therapeutics recognizes the needs of over a quarter of a billion people living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
01/02/18 | $67,000,000 | Series D |
6 Dimensions Capital ArrowMark Partners Clough Capital Partners Efung Capital InterWest Partners Quan Capital | undisclosed |